To the best of our knowledge, we were the first to report MCT expression in prostate cancer [12,13], however, there is a recent study [14] evaluating the role of MCTs in prostate drug resistance and progression but this study does not evaluate neither MCT isoform 2 (MCT2) nor gp70, its known chaperone. Here, SLC16A1 is linked to prostate carcinoma.